著者

今井 俊吾 山田 武宏 西村 あや子 沖 洋充 熊井 正貴 宮本 剛典 笠師 久美子 井関 健

出版者

Japanese Society of Drug Informatics

雑誌

医薬品情報学 (ISSN:13451464)

巻号頁・発行日

vol.16, no.4, pp.169-178, 2015 (Released:2015-03-10)

参考文献数

13

---

Objective: To attain optimal blood concentration rapidly, it is needed to perform initial dose setting appropriately when vancomycin (VCM) used.  In order to design initial dose settings of VCM more currently, we compared the predictive performance of two types of VCM therapeutic drug monitoring (TDM) analysis software retrospectively.Method: We utilized two TDM analysis software, SHIONOGI-VCM-TDM ver.2009 (VCM-TDM) and “Vancomycin MEEK TDM analysis software Ver. 2.0” (MEEK), based on patient’s background. 112 patients who received VCM and performed TDM were analyzed during the period from October 2011 through September 2012 and compared the actual trough level with the predictive trough level.  The predictive performance was evaluated by calculating ME (mean prediction error), MAE (mean absolute prediction error), and RMSE (root mean squared error).  Age, gender, and a renal function were evaluated as patient’s background.Results: VCM-TDM gave good predictive performance for patients overall.  When classified patient’s background complexly (sex, age, and renal function), as for male patients, VCM-TDM showed good predictive performance except for the group over 65 years old and CCr over 85 mL/min.  For female patients, the difference of predictive performance was not accepted by all groups.Conclusion: These results suggest, for male patients, we should use VCM-TDM for initial dose settings except for the group over 65 years old and over CCr 85 mL/min.  For the other patients, we consider that both of software can be used.  These new findings seem to contribute to proper dosage settings of VCM.

著者

笠師 久美子

出版者

公益社団法人 日本薬理学会

雑誌

日本薬理学雑誌 (ISSN:00155691)

巻号頁・発行日

vol.137, no.2, pp.65-67, 2011 (Released:2011-02-10)

参考文献数

5

被引用文献数

2

---

本来,スポーツは健全な心身のもとに競技が行われるべきであるが,薬物等の誤用や濫用による「ドーピング」が社会問題にまで発展している.これは一部の作為的な行為によるものばかりではなく,医薬品やドーピングに関する知識不足による使用も多く含み,結果的に同様の制裁を受けるのが現状となっている.2007年にドーピング防止ガイドラインが文部科学省により策定され,薬剤師も積極的にドーピング防止活動に努めることが明記された.ドーピング撲滅のために薬剤師が介入できる事項としては,薬に関する教育や相談応需,医薬品情報の提供,禁止物質の治療目的使用に係る除外措置(TUE)に関する支援などがあげられる.薬剤師の職務である適正な薬物療法と安全性の担保は,スポーツにおいても求められるところである.そのためには,従来薬剤師が医薬品として理解している「薬物」に加え,ドーピング効果を期待する「薬物」としての情報が求められる.

著者

笠師 久美子

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.129, no.12, pp.1475-1481, 2009 (Released:2009-12-01)

参考文献数

8

被引用文献数

2 5

---

In recent years, appropriate medication and guarantees of safety are being sought not only by medical circles but also by the world of sport. Under normal circumstances, sport should be wholesome in both mind and body, but “doping” by the misuse and abuse of drugs and such is developing into a social issue. This is not just a result of the deliberate behavior of a certain number of people; many cases include use due to a lack of knowledge of drugs and doping, although eventually the sanctions received are the same. Doping tends to be perceived as the problem of just a section of elite athletes, but since the introduction of doping control at the National Athletic Meet 2003, anti-doping measures continue to be a problem close at hand. In 2004, the World Anti-Doping Code came into effect and subsequently not just the world of sport but various national governments became deeply involved with anti-doping. Anti-doping guidelines in Japan were formulated by the Ministry of Education, Culture, Sports, Science and Technology in 2007, stipulating that doctors and pharmacists should be proactive in anti-doping activities. With the aim of eradicating doping, it was deemed that pharmacists can intervene by providing support regarding such issues as drug enlightenment, consultation; the supply of drug information; database production; and therapeutic use exemption. It can be considered that pharmacists can sufficiently use their knowledge and experience gained in these fields, and that such knowledge could lead to more appropriate drug use in sport.

著者

笠師 久美子

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.132, no.12, pp.1325-1328, 2012 (Released:2012-12-01)

被引用文献数

1

---

When athletes consult sports outpatient or orthopedic clinics it is possible to undergo drug treatment with the medical staff having prior knowledge of that patient being an athlete. However, if athletes seek any other diagnosis and treatment as an ordinary patient, the possibility of medical staff realizing the potential for imposing a doping issue on the athlete is extremely low. As a result, if the athlete fails to provide medical staff with information regarding anti-doping regulations when receiving clinical treatment, drug treatment administered as part of medical practices could be viewed as doping, resulting in the athlete being disciplined. In order to avoid this, pharmacist should participate in training in order to be able to provide information for anti-doping purposes. It is my personal opinion that knowledge regarding anti-doping is something that should be shared by all pharmacists, as pharmacists are educated in the fields of pharmacology and pharmacokinetics during the pharmacy education process, and sports pharmacology is a part of this. However, in order for pharmacists to understand sports pharmacology, it is necessary to provide education not only on the benefits and adverse effects of pharmaceutical products, but also on the concept of banned substances. It can be considered one of the pharmacist's duties to protect athletes who purchase drugs at a pharmacy or consult medical institutions as patients. With this, I would like to propose considering the potential for introducing sports pharmacology to pharmaceutical education, and specialist pharmacist training in the sports spectrum.

著者

長田 貴之 柴山 良彦 熊井 正貴 山田 武宏 笠師 久美子 倉本 倫之介 洲崎 真吾 赤澤 茂 真栄田 浩行 坂下 智博 折舘 伸彦 本間 明宏 福田 諭 菅原 満 井関 健

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.38, no.1, pp.51-55, 2012-01-10 (Released:2013-01-10)

参考文献数

14

---

Intractable nausea and vertigo induced by opioid treatment are occasionally difficult to treat. It has been reported that antiemetic drugs and opioid rotation may be effective in treating nausea in such cases; however, this approach has been occasionally ineffective. Symptomatic treatment has not been developed for vertigo induced by opioid treatment. Here, we report a case study where combined treatment with perospirone and a histamine H1 receptor antagonist was used in 2 patients who developed intractable nausea and vertigo induced by opioid treatment. Treatment with a histamine H1 receptor antagonist drug (tablet form, containing 40 mg diphenhydramine salicylate and 26 mg diprophylline) suppressed the nausea and vertigo. However, increasing the opioid dosage exacerbated the symptoms, and treatment involving the histamine H1 receptor antagonist and opioid rotation was ineffective. Subsequently, combination treatment with the histamine H1 receptor antagonist (3 tablets per day) and perospirone (maximum daily dose, 16 mg) improved the symptoms. The results of the present study suggest that combination treatment with a histamine H1 receptor antagonist and perospirone might improve intractable nausea and vertigo induced by opioid treatment.

著者

堤 竹蔵 今井 俊吾 山田 勝久 山田 武宏 笠師 久美子 小林 正紀 井関 健

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.139, no.7, pp.1055-1061, 2019-07-01 (Released:2019-07-01)

参考文献数

20

被引用文献数

2

---

Linezolid (LZD), an antimicrobial agent against methicillin-resistant Staphylococcus aureus, demonstrates good bone and joint penetration, and is used for prosthetic bone and joint infections. Recently, we observed vomiting in several patients administered LZD. However, there are few reports on the incidence rate of, and risk factors for, LZD-induced nausea and vomiting. In this study, we aimed to verify the relationship between LZD administration and vomiting. Patients administered LZD at the Department of Orthopedic Surgery of Hokkaido University Hospital between November 2008 and December 2017 were enrolled in the study. The primary endpoint was the comparison of the vomiting rate between patients administered LZD (LZD group) and those administered other antibiotics (non-LZD group). For the secondary endpoint, to verify the risk factors of vomiting, a univariate logistic regression analysis was performed. In total, 130 patients were included in this study; 77 patients in the LZD group, and 53 in the non-LZD group. Vomiting occurred in 18 patients in the LZD group and 4 patients in the non-LZD group (23.4% and 7.5%, respectively); this was significantly higher in the LZD group. In the univariate logistic regression analysis, LZD administration, gender (female), age ≥65 years, renal impairment (creatinine clearance <60 mL/min) and concomitant use of rifampicin were extracted as potential risk factors of vomiting. The results of this study reveal a possible relationship between LZD administration and vomiting.